These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19904272)

  • 41. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on screening in prostate cancer based on recent clinical trials.
    Sciarra A; Cattarino S; Gentilucci A; Salciccia S; Alfarone A; Mariotti G; Innocenzi M; Gentile V
    Rev Recent Clin Trials; 2011 Jan; 6(1):7-15. PubMed ID: 20868347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
    Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
    Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
    Magnani CJ; Li K; Seto T; McDonald KM; Blayney DW; Brooks JD; Hernandez-Boussard T
    J Natl Compr Canc Netw; 2019 Jul; 17(7):795-803. PubMed ID: 31319390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.
    Garg V; Gu NY; Borrego ME; Raisch DW
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):327-42. PubMed ID: 23763530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
    Pashayan N; Pharoah P; Neal DE; Hamdy F; Donovan J; Martin RM; Greenberg D; Duffy SW
    Int J Cancer; 2011 Mar; 128(6):1462-70. PubMed ID: 20499312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.